Fundraising Fox
Iolyx
10 employees on LinkedIn · 3 known investors
Find your way into Iolyx
1,365 people in our graph can introduce you to the Iolyx team.
Sign up to see every warm intro you have to Iolyx
- Paths you didn't know you had: your email and LinkedIn already hold routes to the Iolyx team. We find them
- 2nd- and 3rd-degree connections: the friend-of-a-friend routes you can't see from your own inbox or LinkedIn
- Answers now, not in days: momentum is everything in a raise. Skip asking around whether someone knows someone
Days of research, done the moment you sign in, with every route ranked by how warm it is.
Iolyx is a pharmaceutical company focused on developing treatments for ocular conditions. The company assembles a team of experienced scientists, clinicians, and regulatory experts in drug development and ophthalmology.
Founders & leadership
EJ
Elizabeth JeffordsCEO & PresidentShe previously held senior leadership roles at Roche and Genentech, including heading the Global Established Products Business Unit and overseeing the US ophthalmology business, with experience across commercial operations, product development, and regulatory affairs.
SD
Shannon DahlChief Scientific OfficerWith extensive experience in biotech, she has worked across R&D strategy, clinical development, regulatory affairs, and commercialization phases from early-stage research through Phase 3 trials.
BB
Bryan BoyleChief Legal & Administrative OfficerBryan Boyle serves as Chief Legal & Administrative Officer at Iolyx, which develops treatments for ocular conditions. He has prior experience in intellectual property prosecution and litigation within biotech and pharma, along with transaction management and contract negotiation, and previously held the position of Vice President Legal at Alkahest, Inc.
Investors · 3
Alumni Ventureslisted by Alumni VenturesManchester · $100K – $10M
How we know: av.vc · Not right? Tell us
Frazier Life Scienceslisted by Frazier Life SciencesPalo Alto
How we know: Frazier Life Sciences's portfolio page · funding news · Not right? Tell us
Frazier Healthcare PartnersreportedSeattle · $50M – $400M
How we know: a partner's Signal profile · Not right? Tell us
In the news
Frequently asked questions
- What does Iolyx do?
- Iolyx is a pharmaceutical company focused on developing treatments for ocular conditions. The company assembles a team of experienced scientists, clinicians, and regulatory experts in drug development and ophthalmology.
- Who are Iolyx's investors?
- Iolyx's investors include Alumni Ventures, Frazier Life Sciences, Frazier Healthcare Partners.